PPAR gamma

• 

  Subject Areas on Research

  • A de novo deafwaddler mutation of Pmca2 arising in ES cells and hitchhiking with a targeted modification of the Pparg gene. 
  • Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. 
  • Activation of Human Peroxisome Proliferator-Activated Nuclear Receptors (PPARγ1) by Semi-Volatile Compounds (SVOCs) and Chemical Mixtures in Indoor Dust. 
  • Alternative splicing in Acad8 resulting a mitochondrial defect and progressive hepatic steatosis in mice. 
  • Antifibrotic therapies: will we ever get there? 
  • Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. 
  • CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. 
  • CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. 
  • Characterizing the peroxisome proliferator-activated receptor (PPARγ) ligand binding potential of several major flame retardants, their metabolites, and chemical mixtures in house dust. 
  • Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. 
  • Cyclooxygenase (COX) inhibitors and the intestine. 
  • Decreased PPAR gamma expression compromises perigonadal-specific fat deposition and insulin sensitivity. 
  • Delayed fracture healing and increased callus adiposity in a C57BL/6J murine model of obesity-associated type 2 diabetes mellitus. 
  • Disruption of Nuclear Receptor Signaling Alters Triphenyl Phosphate-Induced Cardiotoxicity in Zebrafish Embryos. 
  • Effect-Directed Analysis of Human Peroxisome Proliferator-Activated Nuclear Receptors (PPARγ1) Ligands in Indoor Dust. 
  • Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. 
  • Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. 
  • From Prescription to Transcription: Genome Sequence as Drug Target. 
  • GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. 
  • Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population. 
  • In vitro assessment of human nuclear hormone receptor activity and cytotoxicity of the flame retardant mixture FM 550 and its triarylphosphate and brominated components. 
  • Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer. 
  • Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis. 
  • Ligand binding and activation of PPARγ by Firemaster® 550: effects on adipogenesis and osteogenesis in vitro. 
  • MuRF2 regulates PPARγ1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet. 
  • Muscle ring finger-3 protects against diabetic cardiomyopathy induced by a high fat diet. 
  • Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. 
  • Ontogeny and nutritional control of adipogenesis in zebrafish (Danio rerio). 
  • PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. 
  • PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. 
  • Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. 
  • Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter. 
  • Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction. 
  • Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice. 
  • Probing the role of PPARγ in the regulation of late-onset Alzheimer's disease-associated genes. 
  • Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2. 
  • Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. 
  • Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. 
  • The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. 
  • The effects of PPARγ on the regulation of the TOMM40-APOE-C1 genes cluster. 
  • The high-production volume fungicide pyraclostrobin induces triglyceride accumulation associated with mitochondrial dysfunction, and promotes adipocyte differentiation independent of PPARγ activation, in 3T3-L1 cells. 
  • The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. 
  • Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism. 
  • Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? 
  • Transgenic ω-3 PUFA enrichment alters morphology and gene expression profile in adipose tissue of obese mice: Potential role for protectins. 
  • Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. 
  • Unconventional oil and gas chemicals and wastewater-impacted water samples promote adipogenesis via PPARγ-dependent and independent mechanisms in 3T3-L1 cells. 
• 

  Keywords of People

  • McDonnell, Donald Patrick, Chair, Department of Pharmacology & Cancer Biology, Duke Innovation & Entrepreneurship